Tek doz tadalafil 20 mg verildikten üç saat sonra idrar akım hızını arttırmaktadır

AMAÇ: Hastalarda klinik ve yaşam kalitesindeki iyileşmelere rağmen, PDE5 inhibitörlerinin idrar akış hızı ve postmiksiyonel rezidüel idrar hacmi (PVR) üzerindeki etkisi halen tartışmalıdır. Bu çalışmada, bir PDE5 inhibitörü olan tadalafilin üroflovmetrik parametreler ve PVR üzerindeki akut etkilerini değerlendirdik. GEREÇ ve YÖNTEM: Erektil disfonksiyonu olan 127 erkeğe demografik bilgilerini de içeren anketler dolduruldu ve PVR için üroflovmetri ve ultrasonografi yapıldı. Hastalar daha sonra 20 mg tadalafil aldı. Üç saat sonra üroflovmetri ve ultrasonografi tekrarlandı. Tadalafil öncesi ve tadalafil sonrası üroflovmetrik parametreler ve PVR değerlendirildi ve karşılaştırıldı. P değeri 0,05’ten küçük olduğunda fark istatistiksel olarak anlamlı kabul edildi. BULGULAR: 127 erkeğin yaş ortalaması 49,7±12,3 idi. Tadalafil öncesi ortalama maksimum akış hızı değeri 16,8±5,0 ve tadalafil sonrası ortalama maksimum akış hızı değerleri 18,1±5,1 idi (p

Single dose tadalafil 20 mg increases urine flow rates 3 hours administration

OBJECTIVE: Despite clinical and quality of life improvements in patients, the effect of PDE5 inhibitors on urine flow rate and post-void urine volume is still controversial. In this study, we evaluated the acute effects of tadalafil, a PDE5 inhibitor, on uroflowmetric parameters and postvoid residual urine volume (PVR). MATERIAL and METHODS: 127 men who were suffering from erectile dysfunction filled out questionnaires providing demographic information and underwent uroflowmetry and ultrasonography for residual urine volume. The patients then received 20 mg of tadalafil. Three hours later, the uroflowmetry and ultrasonography were repeated. The pre-tadalafil and post-tadalafil uroflowmetric parameters and PVR were evaluated and compared. Differences were considered statistically significant when the p value was less than 0.05. RESULTS: The mean age of the 127 men was 49.7±12.3. The mean pre-tadalafil maximal flow rate value was 16.8±5.0, and the mean post-tadalafil maximal flow rate values was 18.1±5.1 (p

PDF

___

1. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838–45. [CrossRef]
2. Macfarlane GJ, Botto H, Sagnier PP, Teillac P, Richard F, Boyle P. The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol 1996;49:1171–6. [CrossRef]
3. Blanker MH, Bohnen AM, Groeneveld FPM, Bernsen RM, Prins A, Thomas S, Bosch JLHR. Correlates for erectile and ejaculatory dysfunction in older Dutch men: A community-based study. J Am Geriatr Soc 2001;49:436–42. [CrossRef]
4. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, et al. Pharmacotherapy for erectile dysfunction. J Sex Med 2010:7;524–40. [CrossRef]
5. Uckert S, Küthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166:2484–90. [CrossRef]
6. Kedia GT, Uckert S, Kedia M, Kuczyk MA. Effects of phosphodiesterase inhibitors on contraction induced by endothelin‐1 of isolated human prostatic tissue. Urology 2009;73:1397–401. [CrossRef]
7. Hieble JP, Ruffolo RR Jr. The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res 1996;33:145–60. [CrossRef]
8. Tinel H, Stelte-Ludwig B, Hütter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98:1259– 63. [CrossRef]
9. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van Ende den G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double‐ blind trial. J Urol 2007;177:1071–7. [CrossRef]
10. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo‐controlled study to assess the efficacy of twice‐daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236–44. [CrossRef]
11. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion‐Mboussa A, Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010;105:502–7. [CrossRef]
12. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804–14. [CrossRef]
13. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228–34. [CrossRef]
14. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, et. al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9:271–81. [CrossRef]
15. Karami H, Hassanzadeh-Hadad A, Fallah-Karkan M. Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial. Urol J 2016 8;13:2920–6. http://journals.sbmu.ac.ir/urolj/ index.php/uj/article/view/3666/1102
16. Carson CC, Rosenberg M, Kissel J, Wong DG. Tadalafil - a therapeutic option in the management of BPH-LUTS. Int J Clin Pract 2014;68:94– 103. [CrossRef]
17. AUA. Practice Guidelines Committee American Urological Association guideline: on the management of benign prostatic hyperplasia (BPH). Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (2018, amended 2019). Erişim: https://www.auanet.org/guidelines/ benign-prostatic-hyperplasia/lower-urinary-tract-symptoms
18. Guven EO, Balbay MD, Mete K, Serefoglu EC. Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int Urol Nephrol 2009;41:287–92. [CrossRef]
19. Öztürk MI, Koca O, Sertkaya Z, Keles MO, Kaya C, Karaman MI. Acute effects of sildenafil on uroflowmetric parameters in erectile dysfunction patients with and without lower urinary tract symptoms. J Androl 2012;33:1165–8. [CrossRef]
20. Reynard JM, Peters TJ, Lim C, Abrams P. The value of multiple freeflow studies in men with lower urinary tract symptoms. Br J Urol 1996;77:813–8. [CrossRef]